← Leaderboards
Lorne M Golub
Traverse Biosciences, Inc.
$763,071
Attributed
$1,526,141
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $888.8K · FY2015–17$1M$750K$500K$250K$0
'15
'16
'17
Funding mix
By agency
NIH$1,526,141 · 2
By mechanism
R42$1,320,432 · 1
R41$205,709 · 1
Top collaborators
- Ying Gu3 shared
Others in their field
Top investigators on “Commercial Application”
- John C Reed · University Of Texas Md Anderson Can Ctr$65,013,624
- David Heimbrook · Leidos Biomedical Research, Inc.$57,723,265
- Martha Hering · Westat, Inc.$57,098,843
- Tommaso Melodia · Suny At Buffalo$42,392,131
- Dennis L Matthews · University Of California-Davis$39,323,652
- Eric Baer · Case Western Reserve University$37,136,000
Research focus
Commercial ApplicationDrug CandidateCenters For Disease Control And Prevention (U.S.)ChronicDiabetes MellitusAgedBone ResorptionCellsAdultChemokineCurcuminCytokineAnti-InflammatoryAnti-Inflammatory AgentsArachidonic AcidsAreaAlveolar BoneCanis FamiliarisAlveolar Bone LossBiologicalAnalogBone LossAdverse EffectsDrug Development
Grant awards (3)
Pre-Clinical Safety and Efficacy of TRB-N0224 for the Treatment of Periodontal Disease$431,622
R42 · FY2017 · DE · contact PI
Pre-Clinical Safety and Efficacy of TRB-N0224 for the Treatment of Periodontal Disease$888,810
R42 · FY2016 · DE · contact PI
Evaluation of TRB-N0224, a Proprietary Chemically Modified Curcumin, for the Treatment of Periodontal Disease in a LPS-Induced Rat Model$205,709
R41 · FY2015 · DE · contact PI